» Articles » PMID: 31572511

Gene Delivery into Hepatic Cells with Ternary Complexes of Plasmid DNA, Cationic Liposomes and Apolipoprotein E-derived Peptide

Overview
Journal Exp Ther Med
Specialty Pathology
Date 2019 Oct 2
PMID 31572511
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Cationic liposomes containing a cationic lipid, such as 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), have often been used for the transduction of plasmid DNA (pDNA) . However, such liposomes induce gene expression primarily in the lungs after intravenous injection. To improve the delivery of cationic liposomes/pDNA complexes (pDNA lipoplexes) to the liver by intravenous administration, the current study synthesized two apolipoprotein E (ApoE)-derived peptides, dApoE-R9 and ApoE-F-R9, for liver targeting via certain ApoE receptors, including the low-density lipoprotein receptor. Ternary complexes of pDNA, cationic liposomes and ApoE-R9 peptide were also prepared. After transfection, ternary complexes with DOTAP/1,2-dioleoyl--glycero-3-phosphoethanolamine (DOPE) liposomes exhibited high transfection activity in HepG2 cells compared with DOTAP/cholesterol (Chol) liposomes. In particular, ternary complexes with dApoE-R9 exhibited high transfection activity in cells compared with ApoE-F-R9. However, transfection studies revealed that ternary complexes with DOTAP/DOPE liposomes and dApoE-R9 did not increase gene expression in the liver compared with DOTAP/DOPE lipoplexes. In contrast, ternary complexes with DOTAP/Chol liposomes and dApoE-R9 increased gene expression in the liver compared with DOTAP/Chol lipoplexes. The results demonstrated that the optimal liposomal formulation in ternary complexes with ApoE-R9 peptide for liver delivery were different from those that were .

Citing Articles

Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review.

Rodriguez-Castejon J, Beraza-Millor M, Solinis M, Rodriguez-Gascon A, Del Pozo-Rodriguez A Drug Deliv Transl Res. 2024; 14(10):2615-2628.

PMID: 38587758 PMC: 11383842. DOI: 10.1007/s13346-024-01583-0.

References
1.
Rensen P, Schiffelers R, Versluis A, Bijsterbosch M, Van Kuijk-Meuwissen M, Van Berkel T . Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents. Mol Pharmacol. 1997; 52(3):445-55. DOI: 10.1124/mol.52.3.445. View

2.
Zhang Y, Bradshaw-Pierce E, DeLille A, Gustafson D, Anchordoquy T . In vivo comparative study of lipid/DNA complexes with different in vitro serum stability: effects on biodistribution and tumor accumulation. J Pharm Sci. 2007; 97(1):237-50. DOI: 10.1002/jps.21076. View

3.
Palaschak B, Herzog R, Markusic D . AAV-Mediated Gene Delivery to the Liver: Overview of Current Technologies and Methods. Methods Mol Biol. 2019; 1950:333-360. DOI: 10.1007/978-1-4939-9139-6_20. View

4.
Igarashi S, Hattori Y, Maitani Y . Biosurfactant MEL-A enhances cellular association and gene transfection by cationic liposome. J Control Release. 2006; 112(3):362-8. DOI: 10.1016/j.jconrel.2006.03.003. View

5.
Getz G, Reardon C . Apoprotein E and Reverse Cholesterol Transport. Int J Mol Sci. 2018; 19(11). PMC: 6275009. DOI: 10.3390/ijms19113479. View